MiNK Therapeutics (INKT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MiNK Therapeutics, Inc. has secured a financial agreement with Agenus Inc., involving a convertible promissory note worth up to $5.0 million. This arrangement allows MiNK Therapeutics to access funds as needed, subject to Agenus’s approval, at an annual interest rate of 2%. The note is repayable on demand after January 1, 2026, and can be settled in cash or equity in the event of a qualified financing event. This move could signal a strategic growth phase for MiNK Therapeutics, potentially piquing the interest of investors monitoring the biotech sector.
For further insights into INKT stock, check out TipRanks’ Stock Analysis page.